Rethinking cancer clinical trials for COVID-19 and beyond

The risks posed to patients with cancer by the current COVID-19 pandemic demand rapid structural changes in healthcare delivery, with many positive changes likely to continue long term. An immediate critical reassessment of trial methodology based on clinical and scientific priorities is essential t...

Full description

Saved in:
Bibliographic Details
Published inNature cancer p. 1
Main Authors Doherty, Gary J, Goksu, Mehmet, de Paula, Bruno H R
Format Journal Article
LanguageEnglish
Published England 01.06.2020
Subjects
Drug development
Clinical trial design
Online AccessGet more information

Cover

More Information
Summary:The risks posed to patients with cancer by the current COVID-19 pandemic demand rapid structural changes in healthcare delivery, with many positive changes likely to continue long term. An immediate critical reassessment of trial methodology based on clinical and scientific priorities is essential to ensure the resilience of clinical cancer research and optimize patient-centered care.
ISSN:2662-1347
DOI:10.1038/s43018-020-0083-x